Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:NPJ Breast Cancer
Main Authors: Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782714/
https://ncbi.nlm.nih.gov/pubmed/33397968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-020-00208-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki